baber/WOPTO huggingface dataset:
Patent NZ-514086-A (NZ)
Title: Compositions containing stannous fluoride for the treatment of hypersensitive teeth
Inventor: DODD GREGORY P
IPC: A61K33/24
Filed: 2000-03-10
Abstract: A desensitizing agent for the cleaning and treatment of sensitive teeth in which the essential desensitizing ingredient is a combination of a first desensitizing agent in an amount of about 0.1 to about 2 wt. % of SnF2, and a second desensitizing agent in an amount of about 0.1 to about 20 wt. % of a water soluble or water swellable polyelectrolyte. Dentifrice compositions employing the desensitizing agent of the present invention surprisingly exhibit excellent organoleptic and flavor release properties.
Patent NZ-514234-A (NZ)
Title: N-cyanomethylamides as protease inhibitors
Inventor: BRYANT CLIFFORD M
IPC: C07D209/52
Filed: 2000-03-15
Abstract: Disclosed are N-cyanomethyl amide compounds of formula (I), wherein R1 is a group of formula (a), and the remaining substituents are defined herein. The compounds are used in the manufacture of medicaments for use as cysteine protease inhibitors in the treatment of disorders mediated by cathepsin S activity.
Patent NZ-516367-A (NZ)
Title: A flavonoid extract for use as an antioxidant
Inventor: STENSWICK LARRY ELLSWORTH
IPC: C07D311/62
Filed: 2001-12-24
Abstract: Disclosed is the use of a flavonoid extract in the manufacture of a medicament for the treatment of a mammal for at least one of the treatments selected from the group consisting of: to reduce or prevent naturally occurring protein oxidation in a mammal's body; to reduce or prevent naturally occurring DNA damage in a mammal's body; and combinations thereof; wherein the extract is obtained from the bark of the genus PInus (such as Pinus radiata) and contains a mixture of flavonoids selected from the group consisting of catechin; epicatechin; gallocatechin; dimers, trimers, oligomers and polymers of catechin and epicatechin; quercetin; dihydroquercetin; myricetin; astringenin; pinosylvin; taxifolin; stilbenes; hydroxylstilbenes; phenolic acids; and combinations thereof.
Patent NZ-517882-A (NZ)
Title: Combustion chamber system, for use with powered tools, with multi-stage axially stacked sections
Inventor: ADAMS JOSEPH S
IPC: B25C1/08
Filed: 2002-03-20
Abstract: A final combustion chamber is accommodated internally within a multi-stage axially stacked annular array of pre-combustion chamber sections.
Patent NZ-518873-A (NZ)
Title: Use of organic compounds in the treatment of disease
Inventor: HAEBERLIN BARBARA
IPC: A61K9/00
Filed: 2000-11-28
Abstract: The use of a dry powder comprising (A) formoterol, or a pharmaceutically acceptable salt or solvate thereof, and (B) a pharmaceutically acceptable particulate diluent or carrier, such as lactose, in an amount of from 400 ìg to 5000 ìg per ìg of (A) for the preparation of an inhalable medicament for the treatment of chronic obstructive pulmonary disease.
Patent NZ-521192-A (NZ)
Title: Indole derivatives, process for preparation of the same and use thereof
Inventor: TORISU KAZUHIKO
IPC: A61K31/422
Filed: 2001-03-08
Abstract: Disclosed are indole compounds of formula (I), wherein: R1 is hydroxy, alkoxy, or NR8R9, R2 is H, alkyl, alkoxy, alkoxyalkyl, halogen, amino, trihalomethyl, cyano, hydroxy, benzyl, or 4-methoxybenzyl, R3 is H, alkyl, alkoxy, halogen, trohalomethyl, cyano, or hydroxy, R4 and R5 are independently H, alkyl, alkoxy, alkoxyalkyl, halogen, nitro, amino, trihalomethyl, cyano, or hydroxy, and the remaining substituents are defined herein. The compounds are used in the manufacture of medicaments as DP receptor antagonists. Also disclosed is the intermediate compound 2-methylindole-4-acetic acid.
Patent NZ-525700-A (NZ)
Title: Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5HT-2 receptor
Inventor: NILSSON BJORN M
IPC: C07D413/12
Filed: 2001-11-20
Abstract: Piperazinylpyrazine compounds of the general formula (I) that are suitable as agonists or antagonists of serotonin 5HT-2 are disclosed, wherein R1, R2, X, Y and Z are as described in the specification. Use of these compounds in the manufacture of a medicament for the prophylaxis or treatment of a serotonin-related medical condition, particularly related to the 5-HT2c receptor is also disclosed.
Patent NZ-526963-A (NZ)
Title: Method for regulating an electrolytic cell using measure of solidified bath edge talus
Inventor: BONNARDEL OLIVIER
IPC: C25C/
Filed: 2002-02-26
Abstract: During the production of aluminium by reduction of aluminia dissolved in a molten cryolite bath, a solidified bath talus 15 is formed on the internal walls of the tank and a quantity B, which is sensitive to the evolution of the solidified bath talus and is called the ridge variation indicator, is determined. At least one of the controllable regulators of the operation of the bath, such as the anode-metal distance H, or the control operations of the bath, such as the addition of AlF3, is modified in accordance with the value of the ridge variation indicator. Regulation of cells operating at up to 500kA with a bath having an AlF3 content greater than 11 percent can be achieved without having to take a large number of measurements of the AlF3 content.
Patent NZ-527445-A (NZ)
Title: Nucleotide sequences and protein(s) encoded by such nucleotides for modulation of apoptosis and its use in pharmaceutical treatments
Inventor: BISOGNI RITA
IPC: A61K38/00
Filed: 2002-01-10
Abstract: An isolated polynucleotide comprises a nucleotide sequence selected from SEQ ID NOs: 1, 2, 4, 6, 8, 10-15 or a sequence that encodes a polypeptide having an amino acid sequence selected form the group consisting of SEQ ID NOs: 3, 5, 7, 9, 16-18. Vectors, isolated host cells, polypeptides, antibodies and methods for detecting a polypeptide of identifying compounds that bind to the polypeptide are described. The polynucleotide or polypeptide can be used in the manufacture of a medicament for modulating cell survival or death, for treating a disease selected from neoplasias; degenerative disease in general, i. e. those affections that involve a partial or total loss of the morphological and functional features typical of a cell, a tissue or an organ, so that vital functions are affected, for example brain degenerative diseases, including Parkinson's diseases and other forms of dementia, degenerative diseases of skeletal muscles, including dystrophy, of heart, including myocardium dilating disease, and of other organs or tissues; pathologies involving acute or chronic ischaemia of tissues; pathologies involving excessive or deregulated inflammation, autoimmune diseases, multiple sclerosis, psoriasis, transplantation rejects or graft versus host disease; hyperplasias such as miointimal cell proliferation following angioplasty, dysplasias and similar diseases; AIDS, tuberculosis or other infectious diseases involving apoptosis or cell death; pathologies involving apoptosis or cell death, or to preserve or reconstitute cell compartments and/or tissues in culturing progenitor and in staminal cells to be used in haematology, oncology, transplantation, or reconstructive surgery.
Patent NZ-528119-A (NZ)
Title: Injection syringe having dosage device
Inventor: BONNIER MATS
IPC: A61M5/24
Filed: 2002-02-28
Abstract: The present invention refers to an injection device comprising an outer syringe (5, 5'), which is arranged in connection with an ampoule (2) for medical agent. The ampoule (2) is axially displaceable inside the outer syringe (5, 5'), whereby an indication device (14, 25, 43) is arranged in connection with the ampoule (2), which is established to be uncovered at the mutual displacement, whereby a dosage is adjustable and readable. Further, the present invention refers to a method for adjustment of the dosage in connection with an outer syringe (5, 5'), which is arranged in connection with an ampoule (2) for medical agent, displacing the ampoule (2) inside the outer syringe (5, 5') for uncovering an indication device (25, 43) in connection with the ampoule (2) at the mutual displacement, whereby a dosage is adjusted and read.
Patent NZ-529403-A (NZ)
Title: Pyrazole derivatives for treating HIV
Inventor: JONES LYN HOWARD
IPC: A61K31/496
Filed: 2002-04-04
Abstract: Describes a compound of the formula (I) or a pharmaceutically acceptable salt, solvate or derivative thereof, wherein: either R1 is H, alkyl, cycloalkyl, phenyl, benzyl, halo, -CN, -OR7, -CO2R10, -CONR5R10, or R8 or R9 said alkyl, cycloalkyl, phenyl and benzyl being optionally substituted; R2 is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, phenyl, benzyl, R8 or R9 said alkyl, cycloalkyl, phenyl and benzyl being optionally substituted; or, R1 and R2 when taken together, represent unbranched alkylene, optionally substituted by oxo, optionally wherein one methylene group of said alkylene is replaced by an oxygen or a nitrogen, said nitrogen atom being optionally substituted by R10; R3 is H, alkyl, cycloalkyl, phenyl, benzyl, halo, -CN, -OR7, -CO2R5, -CONR5R5, R8 or R9, said alkyl, cycloalkyl, phenyl and benzyl being optionally substituted; R4 is phenyl, naphthyl or pyridyl, each being optionally substituted by R8, halo, -CN, alkyl, halo alkyl, cycloalkyl, alkoxy, -CONR5R5, OR13, SoxR6, O-(alkylene)-CONR5R5, O-(alkylene)-NR5R5, or O-(alkylene)-OR6. Further described are processes for the preparation of compounds of the formula (I), compositions containing them and the uses of such derivatives. The compounds described bind to reverse transcriptase and are modulators thereof. As such the compounds described are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated, for example disorders caused by HIV such as AIDS.
Patent NZ-529860-A (NZ)
Title: Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases
Inventor: SHARMA MRIDULA
IPC: A61K38/18
Filed: 2003-11-28
Abstract: A novel polypeptide for regulating muscle growth and the use of the polypeptide in regulating or promoting muscle growth and treating conditions associated with muscle growth and muscle wasting.
Patent NZ-530144-A (NZ)
Title: Phenylsulfonyl-1,3-dihydro-2H-indole-2-one derivatives, their preparation and their therapeutic use
Inventor: DI MALTA ALAIN
IPC: A61P9/10
Filed: 2002-07-15
Abstract: Compounds of formula (I), as well as their addition salts with acids or organic salts, their solvates and/or hydrate(s), that exhibit affinity and selectivity for arginine-vasopressin V1b receptors and/or for ocytocin receptors, and further, for certain compounds an affinity for V1a receptors are disclosed. A method for preparing compounds of formula (I), intermediate compounds of formula (IV) useful for their preparation, pharmaceutical compositions containing them and their use for preparing medicines are also disclosed. The variables shown in formula (I) and formula (IV) are as defined in the specification.
Patent NZ-534703-A (NZ)
Title: Cultivation and harvesting of shellfish
Inventor: BURGESS NIGEL
IPC: A01K61/60
Filed: 2002-12-17
Abstract: A floating platform 100 for the cultivation of sessile bivalvia or other sedentary marine creatures or plants cultivated on ropes 250 or nets or other substrate means suspended in water from at least one support means 200 detachably mounted on the floating platform, the platform comprising a generally annular buoyant body free of a central hub, the body being constructed or adapted for individually detachably mounting thereon a distributed array of a plurality of support means each suspending a respective substrate means there from
Patent NZ-536302-A (NZ)
Title: Cancer treatment regime with temozolomide
Inventor: RAGAB MOHAMED H
IPC: C07D487/04
Filed: 2000-03-27
Abstract: Use of temozolomide for treating a patient afflicted with cancer is disclosed, in which temozolomide is administered to the patient for at least two cycles of a cyclical dosing schedule, wherein each cycle has a dosing period of 5 to 25 days, in which temozolomide is administered daily, at a dose of 40 to 150 mg/m2 /day, followed by a rest period of 5 to 14 days in which temozolomide is not administered. Also disclosed is a medical kit for administering temozolomide, having printed instructions for administering temozolomide according to the cyclical dosing schedule set forth above, and a supply of temozolomide in dosage units for at least one cycle, wherein each dosage unit contains 5 to 250 mg of temozolomide and a pharmaceutically acceptable carrier.
Patent NZ-536414-A (NZ)
Title: Dihydroflavonal-4-reductase (DFR) sequences from Festuca arundinacea and Lolium perenne
Inventor: DEMMER JEROEN
IPC: C12N15/82
Filed: 2003-05-06
Abstract: Isolated polynucleotides encoding polypeptides with dihydroflavonal-4-reductase (DFR) activity from the grass Festuca arundiacea (SEQ ID NO: 35/79) and Lolium perenne (SEQ ID NO: 37/81. Also disclosed is a method for modifying the activity of a polypeptide involved in a tannin biosynthetic pathway.
Patent NZ-537542-A (NZ)
Title: Method for producing suspensions of mineral fillers. The thus obtained aqueous suspensions of mineral fillers and the use thereof
Inventor: HUSSON MAURICE
IPC: B01F23/70
Filed: 2003-07-16
Abstract: Disclosed is a process for the preparation of aqueous suspensions of fluid mineral matter, which are able to be pumped and conveyed by an end user immediately after a second filtration stage, optionally followed by a compression, with the use of small quantities of dispersant, and allowed control of the quantities of dispersant present in the filtrate, wherein the process comprises a filtration in two separate stages, operated continuously in relation to each other, optionally followed by a compression.
Patent NZ-539268-A (NZ)
Title: Control system for controlling the feeding and burning of a pulverized fuel in a glass melting furnace
Inventor: SOLIS MARTINEZ IVAN JORGE
IPC: C03B5/235
Filed: 2003-10-01
Abstract: A control system for a glass melting furnace, of the type that comprises a series of burners arranged in the glass melting furnace, and which are used alternately to carry out combustion and non-combustion cycles for the melting of the glass is disclosed. The glass melting furnace includes at least one storage silo for storing and feeding pulverized fuel, at least one pulverized fuel feeding system which is filled up and emptied out with the pulverized fuel for providing a flow of the pulverized fuel to each of the burners during a glass melting process, and a control system. The control system comprises: (a) means for controlling the filling up and emptying out of the pulverized fuel feeding system based on measurement and monitoring of the amount of pulverized fuel being stored and fed by the pulverized fuel feeding system; (b) means for monitoring at least one operating variable involved with the glass melting furnace, based on at least one sensor, where the or each sensor detects a different variable during the glass melting process; and (c) means for controlling the alternation of the combustion and non-combustion cycles of the burners in the glass melting furnace, based on the monitoring and feeding of the pulverized fuel to each burner, based on the operating variables of the glass melting process, wherein the means for controlling the filling up and emptying out of the pulverized fuel feeding system, the means for monitoring at least one operating variable involved with the glass melting furnace, and the means for controlling the alternation of the combustion and non-combustion cycles of the burners in the glass melting furnace, are connected to a network communications means.
Patent NZ-541535-A (NZ)
Title: Biodegradable polyurethane composite for osteoimplants
Inventor: KNAACK DAVID
IPC: A61K6/884
Filed: 2004-02-04
Abstract: Biological-based polyurethanes and methods of making the same are disclosed. The polyurethanes are formed by reacting a biodegradable polyisocyanate (such as lysine diisocyanate) with an optionally hydroxylated biomolecule to form polyurethane. The polymers formed may be combined with ceramic and/or bone particles to form a composite, which may be used as an osteoimplant. Particularly disclosed is a biodegradable polyurethane composite, comprising: a polyurethane matrix formed by reaction of a polyisocyanate with a biological material to form a biodegradable polyurethane polymer, wherein the biological material is selected from an optionally hydroxylated biomolecule, a small molecule, a bioactive agent, bone, demineralized bone, mineralized bone, modified forms of the above, or combinations of any of the above. The optionally hydroxylated biomolecule may be selected from the group consisting of phospholipids, fatty acids, cholesterols, polysaccharides, starches, and combinations and modified forms thereof.
Patent NZ-544068-A (NZ)
Title: Composite material having the appearance of natural stone
Inventor: ONG IVAN W
IPC: C04B26/02
Filed: 2004-01-30
Abstract: Disclosed is a composite material having an appearance similar to that of natural stone, said material comprising: a natural aggregate a polymeric binder, a curing agent, and an antimicrobial agent, wherein said antimicrobial agent is an organic antimicrobial agent.
Patent NZ-546055-A (NZ)
Title: Novel tricyclic nucleosides or nucleotides as therapeutic agents
Inventor: COOK PHILLIP DAN
IPC: A61K31/7064
Filed: 2004-08-27
Abstract: Disclosed is a compound of the formula (I) which may be a D- or L-nucleotide or nucleoside, wherein A is O, S, CH2, NH, CHF, or CF2; R1, R2, R2', R3, R3' and R4 are independently selected from the group consisting of H, F, Cl, Br, I, OH, SH, NH2, NHOH, NHNH2, N3, COOH, CN, CONH2, C(S)NH2, COOR, R, OR, SR, SSR, NHR, and NR2; provided that at least one of R2 or R2' is not hydrogen; B is a base selected from the group of heterocycles as defined by formula (II) or formula (III), and wherein the other substituents are as defined herein. Also disclosed is the use of compounds including those defined above in the manufacture of a medicament for the treatment of a viral or bacterial infection, wherein the medicament optionally comprises one or more active anti-viral or anti-bacterial agents.
Patent NZ-547566-A (NZ)
Title: Low power control system and associated methods for a water heater with flammable vapor sensor
Inventor: HOTTON BRUCE A
Filed: 2006-05-30
Abstract: A fuel fired water heating apparatus is disclosed. The water heating apparatus includes: (a) a burner (26) adapted to receive fuel and combustion air and create a flame (60) therefrom, (b) a normally closed fuel valve coupled to the burner for supplying fuel thereto when opened, (c) a thermoelectric circuit (50) which has, connected in series, a thermoelectric device (58) positioned to receive heat from the flame (60) and responsively generate an electrical voltage, a solenoid structure (36) operative to receive electrical power from the thermoelectric device (58) and hold the normally closed fuel valve in an open position and a normally open switch device (61), (d) a low power electrical control circuit (52), which is operable by an electrical power source (72) and coupled to the thermoelectric circuit (50) only via the normally open switch device (61), which is for protecting the heating apparatus against an undesirable operating condition. The low power electrical control circuit (52) has connected therein a variable resistance sensor (46) which is operative to detect the undesirable operating condition. The control circuit (52), in the absence of detection of an undesirable operating condition by the sensor (46), outputs an electrical signal to the switch device (61) to maintain it in a closed state. The switch device (61) terminates the electrical signal upon detection of an undesirable operating condition by the sensor (46) to return the switch device (61) to its normally open state.
Patent NZ-551485-A (NZ)
Title: Wave energy converter
Inventor: GARDINER ALISTER
Filed: 2006-11-21
Abstract: A floating wave energy converter is disclosed. The converter includes an elongate reactive body (14) that is substantially submerged in a vertically upright position in a body of liquid. The centre of mass of the reactive body is located towards its bottom end and below its centre of buoyancy. The reactive body pitches about a centre of rotation located towards its bottom end in response to wave motion. An active float (12) that floats on the surface of the liquid (8) is pivotally coupled to top end of the reactive body about a single pivot axis (16). The active float heaves and surges in response to wave motion, and a power output system is driven by the pivoting movement of the active float about the pivot axis.
Patent NZ-554242-A (NZ)
Title: Catheter
Inventor: IGUCHI MASANOBU
IPC: A61M25/01
Filed: 2005-10-04
Abstract: A catheter 11 with two lumens 11a, 11b formed by an internal wall 16 and with X ray opaque sections 17a, 17b formed on the outer tube 15 at the first and second intersections of the internal wall with the outer tube 15. The peripheral extent of the X ray opaque section on the outer wall at the first intersection a is different from that at the second intersection b. This difference in the peripheral extent of the X ray opaque sections on the outer walls helps distinguish between the two lumens 11a, 11b, when X ray imaging of the catheter is done after insertion into the patient.
Patent NZ-554795-A (NZ)
Title: Improvements in and relating to hair irons
Inventor: OVEREND PAUL
IPC: A45D2/00
Filed: 2005-11-17
Abstract: There is provided a hair iron (1) comprising first and second jaws (3, 5) at least one of which carries a heating element (7, 9), the jaws (3, 5) being moveable between an open configuration and a closed configuration. In one embodiment the iron (1) comprises connector means for connecting to a battery unit (not shown) and a heating element (7, 9) of the iron is arranged to be powered by said battery unit.
Patent NZ-571172-A (NZ)
Title: Joint gap with covering strip supported by formwork allowing relative movement and having apertures for keying
Inventor: EVE PATRICK RONALD
IPC: E01C11/08
Filed: 2007-03-02
Abstract: A joint gap eliminator comprises a substantially planar gap covering strip (3) secured to formwork (2) at one side of a joint of settable material (8). The covering strip (3) extends laterally across the joint so as to be supported at the other side of the joint in a manner which allows relative movement between the other side of the joint and the covering strip (3). Apertures (6) are provided in supporting formwork for keying with the settable material.
Patent NZ-572012-A (NZ)
Title: Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
Inventor: OLSON RICHARD D
IPC: A01N43/04
Filed: 2007-04-23
Abstract: Disclosed herein is an anticancer composition comprising a 13-deoxy anthracycline compound as given, wherein each R1, R2 and R3 individually is H or OH; R4 is H, OH, alkyl, or O-alkyl; R5 is O or NH; and R6 is a guar moiety, pharmaceutically acceptable salts thereof; and a taxane. Preferred 13-deoxy anthracyclines are 13-deoxydoxorubicin, 13-deoxydaunorubicin, 13-deoxycarminomycin, 13-deoxyepirubicin, 13-deoxyidarubicin, 13-deoxyannamycirt, 13-deoxyamrubicin and a 5-imino analogs thereof, and said preferred taxanes is selected from paclitaxel or docetaxel. Such compositions are useful in the treatment of cancer.
Patent NZ-574557-A (NZ)
Title: Film structure ,with directionally symmetrical gas barrier qualities, comprising gas barrier layers and no seperate binding layer and method of manufacture
Inventor: ALLEGAERT RUDI
IPC: B29C48/18
Filed: 2007-06-28
Abstract: A film structure (1) with high oxygen barrier qualities is disclosed. The structure (1) consists of at least five layers. Two outer layers (2) are made of a polyolefin. A gas barrier layer (4) is provided on the inside facing side of each of the two outer layers (2). A layer (3) which is made of a foamed synthetic material is provided between the two gas barrier layers (4). The outer layers (2) consist of a mixture of a polyolefin and a binder. This mixture eliminates the need to use separate binding layers that would otherwise be required between the outer layers (2) and the gas barrier layers (4).